As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of t...

While the largest deal of the week, and certainly the one receiving the most attention, has been Actavis' expansion of its branded p...

When was the last time biotech had a really juicy, successful, high-stakes bidding war? Likely the $10.2 billion Pharmasset acquisition...

Since when did biotech’s epicenter move to Pamplona? The bull run has lasted quite a while now, after having gotten an extra goose, if yo...

Our knee-jerk reaction to Monday’s announcement that Amgen is buying deCODE Genetics for $415 million in cash was “Say what?” It’s hard...

One of the frequent thematic tropes found in the music of Canadian prog-rock trio Rush is the constancy of change, that change is cons...